ArticleNeurology2015
Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.
Article in Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Smoking induces DNA methylation changes in Multiple Sclerosis patients with exposure-response relationship.Scientific reports · 2017Pooled it
- Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.Neurology · 2017Trial
- Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.Current neuropharmacology · 2022Article
- Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2021Article
- CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis.Journal of neuroinflammation · 2020Article
- Age-Related Lymphocyte Output During Disease-Modifying Therapies for Multiple Sclerosis.Drugs & aging · 2020Observational
- Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.Frontiers in immunology · 2020Review
- Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.Therapeutic advances in neurological disorders · 2019Review
- Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.Frontiers in neurology · 2018Article
- The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?Trends in immunology · 2017Review
- Targeting latency-associated peptide promotes antitumor immunity.Science immunology · 2017Article
- Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Immunopathology of multiple sclerosis.Nature reviews. Immunology · 2015Review
- Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis.Frontiers in immunology · 2015Review
- Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo ascertain the mobilization from the bone marrow and the functional relevance of the increased number of circulating hematopoietic stem and progenitor cells (HSPC) induced by the anti-α-4 integrin antibody natalizumab in patients with multiple sclerosis (MS).
methodsWe evaluated CD45(low)CD34+ HSPC frequency by flow cytometry in blood from 45 natalizumab-treated patients (12 of whom were prospectively followed during the first year of treatment as part of a pilot cohort and 16 prospectively followed for validation), 10 untreated patients with MS, and 24 healthy donors. In the natalizumab-treated group, we also assessed sorted HSPC cell cycle status, T- and B-lymphocyte subpopulation frequencies (n = 29), and HSPC differentiation potential (n = 10).
resultsNatalizumab-induced circulating HSPC were predominantly quiescent, suggesting recent mobilization from the bone marrow, and were capable of differentiating ex vivo. Circulating HSPC numbers were significantly increased during natalizumab, but heterogeneously, allowing the stratification of mobilizer and nonmobilizer subgroups. Nonmobilizer status was associated with persistence of disease activity during treatment. The frequency of B cells and CD103+CD8+ regulatory T cells persistently increased, more significantly in mobilizer patients, who also showed a specific naive/memory B-cell profile.
conclusionsThe data suggest that natalizumab-induced circulating HSPC increase is the result of true mobilization from the bone marrow and has clinical and immunologic relevance. HSPC mobilization, associated with clinical remission and increased proportion of circulating B and regulatory T cells, may contribute to the treatment's mode of action; thus, HSPC blood counts could represent an early biomarker of responsiveness to natalizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.